Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data

Fate Therapeutics, Inc. (NASDAQ:FATE) is among the best get rich quick stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their Neutral rating on Fate Therapeutics, Inc. (NASDAQ:FATE), while maintaining their price target of $5.00, implying an upside potential of around 358%. This was after the company presented its T819 data on lupus at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain.

This study, conducted in five patients, revealed that three patients with active lupus nephritis and a history of B-cell-targeted therapy were successful in achieving a primary renal response. The data’s SLEDAI-2K scores showed significant improvement within the one-, six-and-a-half-, and twelve-month periods, indicating a positive performance.

A laboratory scientist testing a small molecule modulator as a potential immune-oncology therapy.

The research firm expressed its eagerness in DORIS remissions to consider FT819 a viable commercial threat. While the early signal of activity has led Fate Therapeutics, Inc. (NASDAQ:FATE) to continue its efforts to accelerate the study, particularly by enrolling at higher doses, the company finds itself on the bleeding edge of engineered cell therapy in autoimmune disease, a market that’s anticipated to reach high levels.

Fate Therapeutics, Inc. (NASDAQ:FATE) is a California-based clinical-stage biopharmaceutical company that focuses on the development of programmed cellular immunotherapies for people living with cancer and immune disorders. Incorporated in 2007, the company is committed to improving the lives of many.

While we acknowledge the potential of FATE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than FATE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.